The Lung Cancer Diagnostic And Screening Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Lung Cancer Diagnostic And Screening Market:
https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report
According to The Business Research Company’s Lung Cancer Diagnostic And Screening Global Market Report 2024, The lung cancer diagnostic and screening market size has grown rapidly in recent years. It will grow from $2.11 billion in 2023 to $2.32 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to growth in digital imaging, standardization of screening protocols, public health initiatives against tobacco use, establishment of cancer registries, advancements in pathology analysis..
The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $3.3 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing incidence of lung cancer, growing emphasis on early detection, expansion of high-risk screening programs, shift towards personalized medicine, government initiatives and funding. Major trends in the forecast period include emergence of novel screening modalities, advancements in biomarker testing, integration of artificial intelligence (ai), rise in liquid biopsy adoption, focus on early stage detection, expansion of low-dose ct screening programs.
The increasing prevalence of lung cancer is expected to propel the growth of the lung cancer diagnostic and screening market going forward. Lung cancer is a malignant disease with symptoms such as coughing, chest pain, and difficulty breathing that is defined by the unchecked proliferation of abnormal cells in the lung tissues. Lung cancer diagnosis and screening help lung cancer patients early diagnose the disease with various tests, including an incisional biopsy and a bronchoscopy. For instance, in January 2023, according to the American Cancer Society, a US-based government organization, in the United States, there were approximately 238,340 new cases of lung cancer (117,550 in men and 120,790 in women). Further, there were reportedly 127,070 deaths from lung cancer (67,160 in men and 59,910 in women). Therefore, the rise in the prevalence of lung cancer is driving the growth of the lung cancer diagnostic and screening market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp
The lung cancer diagnostic and screening market covered in this report is segmented –
1) By Product: Instruments, Consumables And Accessories
2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests
3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer
4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users
Technological innovations are a key trend gaining popularity in the lung cancer diagnostics and screening market. Major companies operating in the lung cancer diagnostics and screening market are introducing innovative technologies to sustain their position in the market. For instance, in December 2021, Auris Health, a US-based robotic medical company, introduced the MONARCH Robotic-Assisted Bronchoscopy procedure, the first MONARCH procedure. This procedure allows physicians to accurately diagnose small and hard-to-reach lung nodules, which enables biopsy for early diagnosis and treatment of lung disease.
The lung cancer diagnostic and screening market report table of contents includes:
1. Executive Summary
2.Lung Cancer Diagnostic And Screening Market Characteristics
3.Lung Cancer Diagnostic And Screening Market Trends And Strategies
4.Lung Cancer Diagnostic And Screening Impact Of COVID-19
5.Lung Cancer Diagnostic And Screening Market Size And Growth
6. Lung Cancer Diagnostic And Screening Segmentation
7.Lung Cancer Diagnostic And Screening Regional And Country Analysis
.
.
.
27.Lung Cancer Diagnostic And Screening Competitive Landscape And Company Profiles
28. Lung Cancer Diagnostic And Screening Key Mergers And Acquisitions
29.Lung Cancer Diagnostic And Screening Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company,
- Thermo Fisher Scientific Inc.
- AstraZeneca PLC
- Abbott Laboratories Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
